Availabio ← Platform Overview

API Reference

Bioavailability intelligence for nutraceutical brands

Quick Start

Start querying right now — no API key required for compound data.

⚠️ Simulation Disclaimer

Pharmacokinetic (PK) simulations return estimates based on published population-average parameters:

  • Not personalized: Individual absorption and metabolism vary by genetics, age, weight, diet, and health status
  • Not clinical measurements: Do not interpret simulation outputs (Cmax, AUC, Tmax) as lab test values
  • Educational only: Results are for research and formulation optimization, not medical diagnosis or treatment
  • Not a medical device: Availabio does not provide medical advice or replace professional healthcare consultation

For B2B users: Include this disclaimer in any consumer-facing output derived from these endpoints.

curl 
curl https://app.availabio.com/api/compounds?search=curcumin&limit=1

✓ This works now. No API key required for read access.

Endpoints

Public Compounds

GET /api/compounds No key needed

List compounds with search, filtering, and pagination.

search string Filter by compound name (e.g. curcumin, magnesium)
evidence_grade A | B | C | D Filter by evidence strength (A = multiple human trials)
page integer Page number (default: 1)
limit integer Results per page (default: 20, max: 100)
GET /api/compounds/:pubchemCid No key needed

Full compound detail including all formulations, pharmacokinetic parameters, CYP metabolism interactions, and DOI-verified sources.

pubchemCid integer PubChem compound ID (e.g. 969516 for Curcumin)

Nested in detail Formulations

Formulation data is returned within the compound detail response. Each formulation includes:

form_name — commercial or descriptive name (e.g. "Micellar (NovaSOL)")
form_category — delivery system type (micelle, phytosome, nanoparticle…)
ba_modifier — bioavailability multiplier vs. standard form (e.g. 185.0 = 185× standard curcumin)
evidence_grade — A–D evidence classification
sources — array of { doi, description } citations

Nested in detail CYP Metabolism

CYP interaction data is returned within the compound detail response. Each entry includes:

enzyme — CYP isoform (e.g. CYP3A4, CYP2C9, CYP1A2)
role — substrate / inhibitor / inducer
inhibition_type — competitive, mechanism-based, mixed
ki_um — inhibition constant in µM where available
evidence_grade — A–D evidence classification
sources — DOI-anchored citations

API Key AI Analysis

POST /api/ai/bioavailability-analysis Key required

Pharmacokinetic bioavailability analysis across formulation options. Interprets PK parameters against dose, formulation, and co-administration context.

POST /api/ai/nutrition-analysis Key required

Supplement interaction and nutrition analysis using the full CYP interaction database and compound dataset.

POST /api/pbpk/analyze-supplement Key required

Full compound analysis with curated PK data, all formulation options with BA modifiers, and CYP metabolism interactions. DOI-sourced evidence for every value.

POST /api/pbpk/compare-formulations Key required

Side-by-side formulation comparison with bioavailability modifiers. Pass two ingredient lists and a goal to get a structured comparison with sourced evidence.

AI analysis endpoints require a Brand Intelligence API key. Contact us to get started.

What You Get

Actual response for Curcumin (PubChem CID 969516) — every value has a published source.

GET /api/compounds/969516 
{
  "compound": {
    "pubchem_cid": 969516,
    "compound_name": "Curcumin",
    "ba_pct": "3.00",
    "bcs_class": "II",
    "half_life_hr": "6.77",
    "reference_dose_mg": "8000.00",
    "evidence_grade": "B",
    "sources": [
      {
        "doi": "10.1158/1055-9965.EPI-07-2693",
        "description": "Vareed et al. 2008 — curcumin conjugate metabolite pharmacokinetics"
      },
      {
        "doi": "10.1055/s-2006-957450",
        "description": "Shoba et al. 1998 — piperine enhancement of curcumin BA"
      }
    ],
    "formulations": [
      {
        "form_name": "Micellar (NovaSOL)",
        "form_category": "micelle",
        "ba_modifier": "185.000",
        "evidence_grade": "A",
        "sources": [{
          "doi": "10.1002/mnfr.201300724",
          "description": "Schiborr et al. 2014 — 185× total curcuminoid AUC vs standard"
        }]
      },
      {
        "form_name": "Phytosome (Meriva)",
        "form_category": "phospholipid complex",
        "ba_modifier": "29.000",
        "evidence_grade": "A",
        "sources": [{
          "doi": "10.1007/s11095-007-9461-1",
          "description": "Cuomo et al. 2011 — Meriva 29× BA vs standard curcumin"
        }]
      },
      {
        "form_name": "BCM-95 (Biocurcumax)",
        "form_category": "volatile oil complex",
        "ba_modifier": "6.930",
        "evidence_grade": "A",
        "sources": [{
          "doi": "10.4103/0250-474X.44591",
          "description": "Antony et al. 2008 — BCM-95 6.93× BA vs standard curcumin"
        }]
      }
    ],
    "metabolism": [
      {
        "enzyme": "CYP1A2",
        "role": "inhibitor",
        "inhibition_type": "competitive",
        "ki_um": "40.300",
        "evidence_grade": "C"
      },
      {
        "enzyme": "CYP2C9",
        "role": "substrate",
        "fm": "0.200",
        "evidence_grade": "C"
      }
    ]
  }
}
28 compounds curated
103+ formulation forms
529 CYP interaction pathways
DOI every value sourced

Authentication

Without API key

  • Read-only compound data
  • All formulations & CYP interactions
  • 30 requests / minute
  • No AI analysis endpoints

With API key

  • Full platform access
  • AI bioavailability + nutrition analysis
  • 120–600 req/min (by tier)
  • Per-key usage tracking & analytics
Authorization header 
Authorization: Bearer avb_YOUR_KEY_HERE

Try the Intelligence

Paste your demo key below and run pharmacokinetic analysis live in-browser — no curl required.

Interactive PK Simulation — Run one-compartment PK simulation with co-administered compounds and CYP interaction modifiers.

POST /api/pk/run-pbpk-interactive 
{"compound_name":"curcumin","dose_mg":500,"weight_kg":70,"co_administered_compounds":["piperine"]}
Note: This Cmax/Tmax value is an estimate derived from published parameters (source DOI provided in response). Individual results will vary. Always include the disclaimer above when presenting these results to end users.

Analyze Supplement — Full pharmacokinetic analysis: curated PK, all formulations with BA modifiers, CYP data.

POST /api/pbpk/analyze-supplement 
{"ingredients": ["curcumin"]}

Compare Formulations — Side-by-side bioavailability comparison with BA modifiers and sourced evidence.

POST /api/pbpk/compare-formulations 
{"formulationA": ["curcumin"], "formulationB": ["curcumin", "piperine"], "goal": "maximize bioavailability"}

For B2B Integrations

Responsibility for End-User Disclaimers

If you integrate Availabio's simulation endpoints into a consumer-facing product, you are responsible for:

  • Displaying the Availabio PK simulation disclaimer (see top of this page) to end users
  • Capturing user acknowledgment of the disclaimer before displaying simulation results
  • Including the DOI sources and evidence grades in any results shown to users
  • Not presenting R values, Ki, or [I]u as clinical measurements

Example: Safe Consumer Display

Format results for end users as:

Curcumin + Piperine: Piperine is a known CYP3A4 inhibitor, which may slow the metabolism of curcumin, potentially increasing its availability in your bloodstream. This is estimated from published research, not measured in your body.

[Learn more about CYP3A4] | [Disclaimer]

Response Schema

cyp_interactions (Array)

Enzyme-level interaction modifiers derived from IVIVE (In Vitro to In Vivo Extrapolation) using user's co-administered compounds and curated CYP kinetic parameters.

Field Type Description
primary_enzyme string CYP enzyme where interaction occurs (e.g., CYP3A4, CYP2D6)
primary_role string Role of the primary compound: "substrate"
interacting_compound string Co-administered compound causing the interaction
interacting_role string "inhibitor" or "inducer" — mechanism of interaction
R number IVIVE activity ratio. R < 1 = inhibition (slower clearance). R > 1 = induction (faster clearance). Formula: R = 1 / (1 + [I]u / Ki)
ki_um number Inhibitor constant (µM) — lower Ki = more potent inhibition. References curated compound_cyp_metabolism table.
inhibitor_Iu_um number Unbound inhibitor concentration at steady state (µM). Derived from: Iu = (F × dose × 1000 × fu) / (Vd × MW)
method string "ivive" = full IVIVE calculation with measured PK data. "ki_tier_fallback" = Ki-based estimate when PK data unavailable.
evidence_grade string A/B/C/D. A = human PK studies, B = meta-analysis, C = in vitro + modeling, D = estimated
source_doi string DOI link to original research publication. Use to verify the Ki or PK parameter used.

Interpretation note: Multiple inhibitors on same enzyme → most potent (lowest R) is selected. Multiple inducers → stack additively. Clearance modifier is combined with these IVIVE values using: ke_final = ke_baseline × clearance_modifier_cyp × clearance_modifier_supplement

Ready to query live?

Request a demo key and test the full API before your next call.

Request a demo key

Email: bseidel@availabio.com  —  Subject: "API Access — [Company Name]"

← Back to Platform Overview

Questions About Disclaimers or Compliance?

If you're building a regulated product or need guidance on disclaimer placement, contact us. We want to help ensure accurate communication to your users.